{
  "alleleExist":true,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"MYCN, a transcription factor, is altered by amplification and overexpression in a variety of cancer types including in neuroblastoma.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":true,
  "lastUpdate":"01/11/2023",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "23334666",
        "25749049"
      ]
    },
    "description":"The MYCN P44L mutation is located in the N-terminal transactivation domain of the protein. This mutation has been identified in neuroblastoma and is a statistically significant hotspot (PMID: 23334666). Multiplex ligation-dependent probe amplification copy number analysis of Wilms tumor patient samples with this mutation demonstrated MYCN P44L is likely activating as measured by overexpression of MYCN (PMID: 25749049).",
    "knownEffect":"Likely Gain-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"P44L",
    "alterationType":null,
    "consequence":null,
    "entrezGeneId":4613,
    "hgvs":null,
    "hugoSymbol":"MYCN",
    "id":null,
    "proteinEnd":null,
    "proteinStart":null,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":true,
  "variantSummary":"The MYCN P44L mutation is likely oncogenic.",
  "vus":false
}